Clinical Trial Update: Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the addition of evolocumab to moderate-intensity statin therapy for lowering LDL-C and assessing cardiovascular adverse even…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Tianjin Chest Hospital | Conditions: Acute Coronary Syndrome, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor | Phase 4 | Status: UNKNOWN